Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation, IL-2, and Ipilimumab for Metastatic Melanoma
NCT03297463Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by Masonic Cancer Center. Planned start Jan 2018; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03297463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297463.